

Pharmacy and Nursing Student Research and Evidence-Based Medicine Poster Session

12-4-2015

#### A Systematic Review of the Cost-Effectiveness of Chemotherapy Regimens

Nicholas Rudy *Cedarville University*, nrudy@cedarville.edu

Hannah Chittenden *Cedarville University*, hchitten@cedarville.edu

David Fisher *Cedarville University,* djfisher@cedarville.edu

Abigail Moon *Cedarville University,* abigailrenemoon@cedarville.edu

Lia G. Hickinbotham *Cedarville University*, liahickinbotham@cedarville.edu

See next page for additional authors

Follow this and additional works at: http://digitalcommons.cedarville.edu/ pharmacy\_nursing\_poster\_session Part of the <u>Pharmacy and Pharmaceutical Sciences Commons</u>

#### **Recommended** Citation

Rudy, Nicholas; Chittenden, Hannah; Fisher, David; Moon, Abigail; Hickinbotham, Lia G.; Bruce, Emily; Blizzard, Eric; Chen, Aleda; and Manion, Chelsea, "A Systematic Review of the Cost-Effectiveness of Chemotherapy Regimens" (2015). *Pharmacy and Nursing Student Research and Evidence-Based Medicine Poster Session*. 67. http://digitalcommons.cedarville.edu/pharmacy\_nursing\_poster\_session/67

This Poster Session is brought to you for free and open access by DigitalCommons@Cedarville, a service of the Centennial Library. It has been accepted for inclusion in Pharmacy and Nursing Student Research and Evidence-Based Medicine Poster Session by an authorized administrator of DigitalCommons@Cedarville. For more information, please contact digitalcommons@cedarville.edu.



#### Authors

Nicholas Rudy, Hannah Chittenden, David Fisher, Abigail Moon, Lia G. Hickinbotham, Emily Bruce, Eric Blizzard, Aleda Chen, and Chelsea Manion



# A Systematic Review of the Cost-Effectiveness of **Chemotherapy Regimens**


Chelsea Manion, PharmD, BCPS, Eric Blizzard, Emily Bruce, Hannah Chittenden, David Fisher, Lia Hickinbotham, Abigail Moon, Nicholas Rudy, Aleda Chen, PharmD, MS, PhD Cedarville University School of Pharmacy

# STATEMENT OF THE PROBLEM


## Background

- Approximately 12 million people are diagnosed with cancer each year.<sup>1</sup>
- In 2010 the cost of cancer treatment was \$125 billion, and it is projected to increase to over \$158 billion by 2020.<sup>2</sup>

# **Estimated New Cancer Cases in the**



#### United States in 2015<sup>3</sup>



- Chemotherapy is a recent intervention in medicine and the number of chemotherapy drugs continues to increase.
- With this increase, there is a need to assess the cost-effectiveness data to help make clinical decisions.
- Studies containing cost-analysis data of specific chemotherapies include:
  - Cost-Benefit Analyses  $\bullet$
  - **Cost-Effective Analyses**
  - Cost-Utility Analyses

## SYNTHESIS OF EVIDENCE

### Systematic Preferences Based on Pharmacoeconomic Analyses and GRADE

**Cost-Minimization Analyses** 

### Significance of the Problem

• There are many studies evaluating costs in regards to chemotherapy treatments. However, there is lacking a comprehensive review of the data for clinicians to use to make cost-effective, quality medical decisions.

# OBJECTIVE

This systematic review will assess the cost-effectiveness of anticancer medications with a special focus on the quality of life of patients undergoing chemotherapy with the intent to form recommendations that unite evidence-based literature with clinical practice.

# LIMITATIONS

- Unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses).
- The design and implementation of available studies suggesting high likelihood of bias.
- Ambiguity of disclosed evidence, including bias, limitations, and threats to validity.
- Imprecision of results, such as wide confidence intervals.
- High probability of publication bias.


# REFERENCES

- 1. Hesketh R. Introduction to cancer biology. 1st ed. New York: Cambridge University Press; 2013:276. Accessed 9/27/2015. 978-1-107-60148-2.


Score				
GRADE Score	Cost Benefit Analysis	Cost-Effective Analysis	Cost-Utility Analysis	Cost- Minimization Analysis
A	Highest	High	Moderate	Low
В	High	High	Moderate	Low
С	Moderate	Moderate	Moderate	Low
D	Low	Low	Low	Lowest
		Table 1		

Articles will be assessed in a categorical fashion according to type of neoplasm.

Final recommendations will be made at the professional judgments of the researchers based on pharmacoeconomic data extracted from studies weighted by preference status.



2. Schnipper L, Davidson N, Wollins D, et al. American society of clinical ONcology statement: A conceptual framework to assess the value of cancer treatment options. . 2015;33(23):2563.





3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015;65(1):5-29.

4. Aparasu R, Bentley J. Principles of research design and drug literature evalutation. Burlington, MA: Jones & Bartlett

Learning; 2014:370. ISBN-13: 9781284038798.

5. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394.

